Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab De-escalation in Crohn's Disease and Ulcerative Colitis
NCT07303686Phase 4Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ustekinumab in Crohn's disease, ulcerative colitis (UC), sponsored by McGill University Health Centre. Started Oct 2025; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07303686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303686.